Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inion explores BMP-4 product for preventing abnormal bone growth:

This article was originally published in Clinica

Executive Summary

Finnish orthopaedics firm Inion has received a patent in Finland covering a genetically modified form of the bone morphogenetic protein BMP-4 that could prevent the abnormal formation of bone in non-bony tissues, a condition known as heterotopic ossification (HO). HO is observed in up to 50% of patients undergoing spinal fusion surgery and in 71% of those receiving total hip replacements, said the Tampere firm. The company, which has also had a US patent issued for its BMP-4 technology, said it is exploring routes to market the product, which may involve an out-licensing deal to commercialise the intellectual property with a partner. There is significant market potential for a product that reduces the incidence of HO in a more cost-effective form, said the firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel